Based upon this successful transfer - and working with our research collaborators, principal investigators and physicians worldwide - Stemedica has developed and is researching proprietary 'multiple cell technology', known as Stemedica MCT™ Formulations, which can be deployed on a customized basis against a wide array of neurodegenerative diseases, debilitating illness and physical abnormalities.

MCT™ Formulations allow the Company to isolate, extract, expand, manufacture and master bank eleven unique lines of immune-privileged adult stem cells. These proprietary lines provide Stemedica with the unique capability of customizing specialized formulations as required to address complex diseases and other debilitating conditions that single cell and single formula treatments simply can’t affect.

The Company’s technology, products, protocols and support services provide Stemedica with distinct and tangible advantages that differentiate it from other companies. Stemedica:

• Successfully acquired, transferred, commercialized and advanced thirty years of research and human treatment experience in stem cells;
• Provides “no option” patients with access to advanced treatment today at Stemedica-accredited Licensed Treatment Centers;
• Uses proprietary processes and procedures for the isolation, preparation and production of multiple adult stem cell lines;
• Utilizes multiple cell technology formulated and customized for disease-specific conditions.
• Deploys treatment protocols designed to address complex patient-specific, medical conditions;
• Maintains strategic relationships with leading hospitals, academic institutions, research and non profit organizations;
• Strictly adheres to all applicable regulatory guidelines for its pre clinical and clinical studies.
  

Multiple Cell Lines:
• Extensive expertise in preparing multiple stem cell lines for transplantation. Cell lines include: Neuronal, Retinal Pigment Epithelium, Ciliary Body, Mesenchymal, Angioblasts, Keratinocytes, Fibroblasts, Hemopoietic, and Endothelial cells.

Immune Privilege:
• Cell preparations are universally compatible and can be used to treat any patient without typing or matching.

Source Independence:
• Elimination of the need for a continued source of fresh donor tissue by establishing master banks of stable cell lines.

Availability of Cells:
• Master banking technology and methodology allows for abundant and continual supply of adult stem cells.

Reliability and Viability:
• Single sourced tissue, subjected to proprietary expansion and replication processes and procedures provides consistency from one cell preparation to the next.

Quality and Safety:
• Testing procedures for cell lines follow strict regulatory guidelines and manufacturing processes adhere to all applicable current good practice standards (cGMP, cGLP, cGTP).

Preservation Optimization:
• Preservation processes ensure cell viability and integrity for future preparations, (e.g. ensuring cells are not destroyed or compromised due to ice crystal formation during freezing or thawing procedures).

Shipping:
• Successful methods have been perfected for preparing and packaging cells for shipment to Licensed Treatment Centers.

Preparation for Treatment:
• Formulations and protocols have been established for multiple cell lines that address disease specific conditions.